Skip to main content
Get your brand new Wikispaces Classroom now
and do "back to school" in style.
Pages and Files
Arben Kojtari's Final Project
arti patel -log
arti patel- final paper
arti patel- final project
Byron Forte- Final Project
Danielle Fagnani- final project
Diane Liu - Final Project
Hai Truong-Final Project
James Brooks Final Project
James Brooks' Log
Kenny B's Log
Kenny Bassione's Final Project
Marcela Garcia-Final Project
MB - Log
MB Final Project
Paul DeGregory - Final Paper
Paul DeGregory - log
Skid Ahmed Log
Sozit Kurtu - Log
Will Stedman Log
Will Stedman_Final Project
Thursday, September 23, 2010
- Joined the cheminfo2010 wikispace and began to think of a molecule to research. A possibility is psilocybin.
Drugs seem to be popular this year - JBB
Thursday, September 30, 2010-
Will be researching 5 properties of the compound p-Cresol.
Assignment 1: 5 Properties of p-Cresol
Density@ 25degC (g/mL)
LD50 Oral-Rat (mg/kg)
-Your style is very aesthetically pleasing to my eyes - JBB
Thursday, October 28, 2010-
Attempted to start an account on SciFinder only to realize I already had one. Good job, me.
Lolz - JBB
Thursday, November 4, 2010-
While researching on PubMed about psilocybin, I found many papers on the use of this drug to treat patients with anxiety problems and other "mood disorders."
Literature found today:
Help Against Headaches
Long-Term Subjective Effects
Rating Altered States
Anxiety in Advanced Cancer Patients
Neuroscience: Mood Disorders
Pain and Anxiety
OCD in Rodents
OCD in Humans
[Excellent collection of articles to start with JCB]
Sunday, November 7, 2010-
After skimming some of the journals I found, I realize that health concerns must also be taken into account when using psilocybin for medicinal purposes. Also, I see many journals are available about the detection methods of psilocybin. Since it comes from mushrooms in various quantities, detections methods are needed to establish just how much is being introduced into the body.
Thursday, November 11, 2010- Journal Summary:
Acute, Subacute and Long-Term Subjective Effects of Psilocybin in Healthy Humans: A Pooled Analysis of Experimental Studies
[Full marks JCB]
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a hallucinogenic drug found in psilobe mushrooms which can be found all around the world.
In 1955, psilocybin began to be researched for medicinal purposes, and in 1959, a sythetic psilocybin for reasearch pusposes.
Clinical studies in the 60s and 70s demonstrated psilocybin having effects similar to those of LSD.
After the high abuse of psychedelic drugs in the 60s, funding became limited for research in this field.
Research resumed in the 90s with studies that used psychedelic drugs to try and determine the neural reasoning behind psychosis and other similar diseases.
More current research shows improvement in anxiety of advanced stage cancer patients and obsessive compulsive disorder in rodents.
This article specifically centers around the long-term subjective effects of psilocybin.
Data from psilocybin experiments were pooled from the years 1999-2008.
All patients receive a placebo and varying doses of psilocybin (45-315ug/kg).
Vitals were monitored intermittently during the experiment.
After 7 hours, all subjects were examined and released.
All subjects were recruited through advertisements and people with family history of mental disorders and substance abuse were turned down.
All psilocybin obtained from the Swiss Federal Office for Public Health.
All subjects were subjected to the Altered States of Consciousness Rating Scale.
6 sujbects were rated by using the Adjective Mood Rating Scale.
A follow-up questionnaire was given to all subjects 8-16 months after consumption.
Of the 110 test subjects, 2 dropped out for non-drug related reasons and 5 subjects were removed due to adverse effects to low dosages.
Results were statistically analyzed using free available computer packages.
Scores in all fields of Altered States of Consciousness Rating scale increased with dosage.
The Mood Rating Scale also showed increase in all fields except for tiredness.
Only 90 of the 110 patients responded to the long-term questionnaire.
Subjects reported no change or decrease in drug intake.
9% of subjects reported "flashback" experience.
12% of subjects reported negative changes in psychological functions. Only 8% reported these to be severe.
Concluded that psilocybin produced and altered state of consciousness with no ceiling effect seenw tih high doses.
Conclusion that psilocybin is well tolerated by the human body and most adverse effects disappear after 24 hours.
In the long terms follow-up, 90% rated the experience to be at least mildly enriching.
Significant reports of long-term change in change of attitude, relationship with he environment and aesthetic experiencing.
No evidence of increase in drug abuse
Saturday December 4, 2010-
Uploaded Interviews and completed final paper.
I'm so tired... -JBB
help on how to format text
Turn off "Getting Started"